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Introduction: Neuromyelitis Optica (NMO) is an autoimmune disease primarily targeting the spinal cord and optic
nerve leading to paralysis and blindness. The discovery of an antibody against the astrocytic water channel,
aquaporin-4 (AQP4), in the majority of patients, has led to the presumption that the antibody was necessary for
disease pathogenesis. The potential role of T cells in the central nervous system, however, has not been thoroughly
examined.
Results: We generated an anti-AQP4 antibody seronegative model of NMO using pathogenic AQP4-reactive T cells
in mice by immunizing AQP4 null mice with peptides corresponding to the second extracellular loop of AQP4, loop
C. When polarized to a Th17 phenotype and transferred to wild-type mice, these cells caused tail and limb
weakness. Histology showed demyelination and T cell infiltration in the spinal cord, optic nerve and brain. Animals
receiving cells re-stimulated in culture with non-specific proteins resulted in no behavioral disease, indicating that
specific targeting of AQP4 is essential for this phenotype.
Conclusions: In summary, we show that AQP4-reactive T cells are sufficient to trigger an NMO-like disease in mice,
independent of antibodies, indicating that pathogenic AQP4-reactive T cells may play a similar role in humans.
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Neuromyelitis optica (NMO) is a relapsing autoimmune
disease primarily targeting the spinal cord and optic nerve
leading to paralysis and blindness [1]. The discovery of the
highly specific anti-aquaporin-4 (AQP4) IgG1 biomarker
implicates an immune reaction against AQP4 evidenced
by both humoral and cellular pathology within acute
NMO lesions [2, 3]. Several previous mouse and rat
models of NMO focused on the role of the circulating
anti-AQP4 antibody in disease pathogenesis concluded
that the antibody by itself is insufficient to induce disease,
but can exacerbate an experimental autoimmune enceph-
alomyelitis induced by myelin-reactive T cells [4–8]. When
the anti-AQP4 antibody has passive access to AQP4 on
astrocytes in the nervous system, there is abundant evi-
dence that the antibody binds to AQP4 and can* Correspondence: mlevy@jhmi.edu
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unless otherwise stated.participate in complement mediated damage to astrocytes
under experimental conditions [9–11]. Collectively, these
studies indicate an important role for the anti-AQP4 anti-
body in enhancing astrocytic damage from NMO relapses
rather than in the triggering of NMO attacks, prompting
the search for other AQP4-specific immune components
that may be involved upstream in the immunopathogen-
esis of NMO. In each passive transfer study, the anti-
AQP4 antibody was only pathogenic in the context of a T-
cell based autoimmune attack on the central nervous
system.
Production of the IgG1 biomarker against AQP4 pre-
sumably requires AQP4-reactive B and T cells for im-
munoglobulin class switching. T cells are also among the
inflammatory cells found in acute NMO lesions and
their role in the immunopathogenesis of this disease has
been the subject of recent studies in which immunodo-
minant AQP4 peptides can trigger T cell activation in
mice [12, 13] . However, despite activating T cells against
AQP4, these rat and mouse models do not develop ahis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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genic T cells responses are limited by a combination of
central and peripheral tolerance or because certain
AQP4 epitopes are not pathogenic.
We used a unique approach to raise pathogenic
AQP4-reactive T cells by immunizing AQP4 null mice
with loop C peptide of AQP4 (AQP4135–153). When adop-
tively transferred into wild type mice after re-stimulation
in culture with Aqp4135–153 peptide, behavioral disease
was not induced though mild T cell infiltration of the cen-
tral nervous system (CNS) was observed. Polarization of
AQP4-reactive T cells to the T-helper-17 led to CNS
inflammation characterized by demyelination and T cell
infiltration into the spinal cord, optic nerve, and brain.
There was no other evidence of solid organ inflammation
despite widespread AQP4 expression in the mouse sup-




Aquaporin-4 null mice, backcrossed onto the C57BL/6
background at least 14 times, were obtained from Erlend
Nagelhus (University of Oslo, Oslo, Norway) and bred in-
house. Female C57BL/6 wild-type mice between 6–8 weeks
of age were purchased from The Jackson Laboratory. All
mice were housed in a pathogen-free 12-h artificial light-
dark cycle and had ad libitum access to food and water.
The Johns Hopkins Institutional Animal Care and Use
Committee approved all experimental procedures.
T cell generation and culturing
Aquaporin-4 extracellular loop peptides (human 56–69,
135–53, and 212–30) were synthesized at the Johns
Hopkins Synthesis & Sequencing Core Facility. Stock solu-
tions of 120 mg/ml were prepared in DMSO. All three pep-
tides were further diluted into phosphate-buffered saline
each at 2 mg/ml and mixed 1:1 with complete adjuvant
containing 8 mg/ml heat-killed M. tuberculosis H37Ra
(Difco) in incomplete adjuvant (Imject; Thermo-Fisher)
[14]. Aquaporin-4 KO and syngeneic C57Bl/6 mice
(Jackson, MA, USA) were immunized in the flanks with a
total of 100 μl of emulsion. Mice were also injected intra-
peritoneally with 250 ng of Pertussis toxin (Tocris) on days
0 and 2. Twenty-three days following immunization,
spleens were harvested and single cell suspensions were
prepared by pushing spleens through 70 μm cell strainers
(Becton Dickenson) using syringe plungers. Red blood cells
were depleted by resuspending each spleen in 2 ml of ACK
lysis solution (Quality Biological, MD, USA) for 2 min at
room temperature, followed by washing with media. Cells
were counted and seeded in 96-well flat bottom plates at
3 × 105 cells per well in RPMI 1640 supplemented with
Glutamax, 1 % non-essential amino acids, 1 % sodiumpyruvate, 1 % antibiotic-antimycotic (Life Technologies,
Inc.), 10 % fetal calf serum (Sigma) and 50 μM betamer-
captoethanol (Sigma). One hundred microliters of
media containing peptide (final concentration: 10 μg/
ml): MOG35–55, AQP456–69 (loop A), AQP4135–53 (loop
C), or AQP4212–30 (loop E) were added to wells in tripli-
cate. Media with no peptide added or containing 0.1 %
DMSO served as “no stimulus (NS)” background controls.
After 4 days in culture in an incubator at 37 °C with 5 %
CO2 in a humidified atmosphere, 10 μl of a solution con-
taining 0.5μCu of 3H-thymidine (Perkin-elmer) were
added to each well and incubated a further 18 h. Cells
were harvested onto filter paper mat. After drying, mats
were treated with scintillation fluid and assayed for 3H
incorporation. Results are expressed as counts per mi-
nute (cpm).
T cell polarization, adoptive transfer and behavioral
scoring
Six to seven week old female aquaporin-4 KO mice were
immunized with an emulsion of 4 mg/ml Complete
Freund’s adjuvant with 1 mg/ml of Loop C peptide
(135–53) on each flank and each shoulder (50 μl per in-
jection site). Ten days following immunization, lymph
nodes (inguinal, lumbar, brachial and axillary) were col-
lected. Single cell suspensions were prepared by forcing
nodes through a 70 μm cell strainer using a syringe plun-
ger. After washing in complete media (RPMI 1640 with
10%FCS, 50 μM β-mercaptoethanol, non-essential amino
acids, sodium pyruvate, HEPES), cells were counted and
seeded into T75 flasks at 6 × 106 cells per ml. Unpolarized
cells were stimulated with peptide only (final concentra-
tion was 50 μg/ml). For Th17 polarization, cells were stim-
ulated with 30 ng/ml IL-6, 20 ng/ml IL-23 (eBiosciences)
and 10 μg/ml of anti-IFNgamma (XMG1.2; BD Biosci-
ences) in addition to peptide. Following 3 days of culture,
cells were harvested, washed with sterile PBS, and 5x106
cells were injected into mice intravenously through their
tail veins. Pertussis toxin (250 ng; Tocris) was injected
intravenously immediately following cells and again two
days later. Behavioral signs and weights were tracked start-
ing 5 days post-transfer of cells, which was quantified
using a standardized 5-point EAE disability scale by a
blinded examiner [14]. Animals were euthanized and
tissues harvested for histological evaluation 14–21 days
following cell transfer.
ELISPOT assay
ELISPOT assay was used to determine the frequency of
cytokine-producing cells in polarized and unpolarized cell
cultures. The day before cells were to be harvested from
immunized AQP4 null mice, the wells of an immobilon P-
bottom 96-well plates (Multiscreen®HTS, 0.45 μm pore
size; EMB Millipore, USA) were pre-wet with 35 % ethanol
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coated with 50 μl of a 1:250 dilution of capture antibody,
anti-IL17 (Th17), provided with ELISPOT Ready-Set-Go
kits (eBioscience). Plates were covered and incubated
overnight at 4 °C. Wells were then washed twice with
coating buffer and once with complete media; plates were
stored in the incubator until cells were prepared. Spleen
and lymph node cells were prepared as described above
and prepared with and without polarizing conditions. Har-
vested cells were 2-fold serially diluted in media containing
3 × 107 irradiated splenocytes (irradiated with 3,500 rads) as
antigen-presenting cells (APCs); APCs mixed 12:1 with
1.25 × 105 lymph node cells per well yielded the most well-
defined spots. After overnight in culture, wells were washed
(TBS + 0.05 % Tween®-20). Detection antibody was diluted
1:250 in diluents provided in the kit and 50 μl applied to
each well for 2 h at RT. After washing, streptavidin-alkaline
phosphatase was added to each well (1:2500; Sigma) for
45 min. After further washing, signal was developed with
development solution containing BCIP and NBT (i.e.
150 mM Tris-HCl, 5 mM MgCl2, 100 mM NaCl, pH9.5
supplemented with 4 mM levamisole (Sigma), 0.15 mg/ml
5-bromo-4-chloro-3-indolyl-phosphate, and 0.36 mg/ml 4-
nitro blue tetrazolium chloride (Roche) for 10 min at room
temperature in the dark. Reaction was stopped by washing
with PBS then distilled H2O before air drying. Spots were
imaged with an Immunospot Series 3 Analyzer (Cellular
Technology, Ltd.) and counted using Image J and the
“find Maxima” function. Results are expressed as the
mean of triplicate values (± standard error of the mean,
SEM) adjusted to per 106 cells per well. Student’s t-test
was performed on data; p<0.05 was considered statisti-
cally significant.
Tissue processing and histology
Animals were anesthetized with isofluorane and perfused
via cardiac puncture first with PBS and then with freshly
prepared 4 % paraformaldehyde solution. The optic nerves
and spinal cords were harvested, fixed overnight, cryopre-
served in 30 % sucrose and frozen for sectioning. After
embedding tissue in O.C.T. Compound (Tissue-Tek®), ten
micron slices sections were mounted on Superfrost Plus
Microscope Slides (Fisher brand). Eriochrome cyanine was
used to identify demyelinating lesions in the sectioned tis-
sue. Eriochrome cyanine solution was prepared by dissolv-
ing eriochrome cyanine in 450 ml 0.5 % H2SO4 (0.2 %)
and 10 % FeCl3 added to a final concentration of 0.4 %.
The sectioned tissue was hydrated by serial washes in
100 % ethanol, 95 % ethanol, 70 % ethanol and distilled
water for 10 min each and then immersed for 15 min in
eriochrome cyanine solution. After staining, differentiation
was carried out in freshly made 0.1 % NH4OH for 20–30 s
and halted by thorough washing in distilled water. Slides
were mounted as described below. Sections werecounterstained with 0.1 % eosin Y in acetate buffer. Im-
munohistochemical staining for CD3+ T cells was per-
formed by washing sections in saline before performing
heat-mediated antigen retrieval in 0.05 M sodium bor-
ate buffer (pH 8.0) in a microwave pressure cooker.
Slides immersed in buffer were heated in the microwave
at full power until full pressure was achieved (5 min)
then heated for an additional 7 min at 20 % power. After
3 min of cooling and flooding of slide container with room
temperature saline, slides were transferred to 3 % H2O2 for
20 min to quench endogenous peroxidases and blocked for
endogenous biotin using an avidin/biotin blocking kit
(Vector Laboratories, Inc.). Non-specific binding was
blocked with 5 % goat serum in 0.1 % Triton®X-100 for
30 min at room temperature. Anti-CD3 rabbit monoclonal
antibody (clone SP7; GeneTex,USA) was applied at 1:75
overnight at 4 °C and detected with biotinylated goat anti-
rabbit IgG (1:1000; Vector Laboratories, Inc.), followed by
Avidin-Biotin Complex-horse radish peroxidase (Vector
Laboratories, Inc.). Signal was developed with 0.5 mg/ml
diaminobenzidine HCl in PBS with 0.03 % H2O2 for
5 min. After washing, slides were Fast Green counter-
stained, dehydrated and mounted. Quantification and ana-
lysis of myelin and CD3 staining was as described [7].
Glial fibrillary acidic protein (GFAP), myelin basic protein
for myelin, and aquaporin-4 were examined by immuno-
fluorescence (without antigen retrieval) applying mouse
anti-GFAP (1:1000; Sigma), rabbit monoclonal anti-MBP
(1:250; Epitomics/ Abcam), and rabbit anti-AQP4 (H-19)
(1:250; Santa Cruz Biotechnology) overnight at 4 °C,
followed by goat Alexa Fluor® 555-conjugated anti-rabbit
IgG and Alexa Fluor® 488-conjugated anti-mouse IgG
(1:250; Life Technologies / Molecular Probes) for 30 min
at RT. Fluorescent sections were mounted with Fluorogel
(Electron Microscopy Sciences) containing 2 μg/ml 4′,6-
Diamidino-2-Phenylindole (DAPI) and sealed with clear
nail polish.
CD3 quantification was performed in a blinded fashion
using background-corrected high resolution images from
areas representing 6–8 levels of the spinal cord, 3 cor-
onal levels of the cerebrum (left and right, for a total of
6 fields of view captured at 4X), or a region from the left
and right lobes of the cerebellum (2 fields at 4X) via Fast
Green staining. Three sections from each optic nerve
were also analyzed (each representing a part of the lon-
gitudinal length of the nerves). Total immunoreactive
(brown DAB reaction product) was expressed as % im-
munoreactive area and mean ± SEM.
Results
In NMO, the anti-AQP4 antibody targets an extracellular
epitope of AQP4 [15]. Using AQP4 null mice, we checked
for antibody production and T cell responses against pep-
tides corresponding to the extracellular loops of AQP4,
Jones et al. Acta Neuropathologica Communications  (2015) 3:28 Page 4 of 8loops A, C and E. AQP4 null mice were used in this model
because these mice do not have to overcome immune tol-
erance to develop pathogenic AQP4-reactive T cells. We
found no evidence of antibody production against any of
the loops. The lack of anti-AQP4 antibody production is
not unexpected as short peptides do not routinely exhibit
robust antibody responses. However, there was a ro-
bust T cell response against the second extracellular
loop of AQP4, loop C (Fig. 1a). In phenotyping these
AQP4-reactive T cells, we found that a significant
number of these unpolarized cells produced bothFig. 1 A. T cell proliferation assay reflecting a robust reaction to loop C
with myelin-oligodendrocyte glycoprotein (MOG) peptide 35–55 showed prolife
the presence of the MOG antigen (red bars). C57Bl6 mice immunized with AQP
AQP4 null mice (KO naïve) do not inherently react to AQP4 peptides unless the
Among those tested, a peptide corresponding to the extracellular loop C gener
against a mix of AQP4 peptides 56–69 (loop A), 135–53 (loop C), and 212–30 (lo
three peptide (yellow bars). Results shown are counts per minute means +/− SE
number of IL-17 and interferon-gamma (IFN-γ) cytokine-producing cells in Th17
AQP4 loop C peptide (AQP4135–53) versus no stimulation (NS). Unpolarized AQP
compared to unstimulated controls. After polarization to a Th17 phenotype, the
IFN-γ producing cells is nearly undetectable, but the frequency of IL-17-produci
cells remains low)interleukin-17 (IL17) and IFN-gamma, compared to
non-stimulus (NS) controls (Fig. 1b). Polarization of
T cells towards the Th17 phenotype (Th17-pol) pro-
duced twice the number of IL17-secreting cells while
the number of IFN-gamma producing cells were
barely detectable (Fig. 1b).
The AQP4 null mice that generated a robust T cell reac-
tion against the second extracellular loop of AQP4, loop
C, did not develop autoimmune neurological disease as
they do not express the target antigen. Even when intra-
venously transferred to wildtype AQP4-expressing C57Bl/of AQP4. T cells from two C57Bl6 mice (wt-MOG) immunized
rative activity as measured by incorporation of tritiated-thymidine only in
4 peptides (wt-AQP4) did not react against any AQP4 antigen. T cells from
mice are immunized with the peptides (KO1-AQP4 and KO2-AQP4).
ated a robust reaction only in T cells from AQP4 null mice immunized
op E), exposed to cells in culture alone (brown bars) or as a mixture of all
M of triplicate reactions. B. ELISPOT assay was used to determine the
polarized (Th17-pol) and unpolarized (unpol) cell cultures exposed to
4-reactive T cells expressed significant levels of both IL-17 and IFN-γ
number of IL-17 producing cells almost doubles while the number of
ng cells also increases in the unstimulated culture (while IFN-γ-producing
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ally meaningful behavioral manifestations or histological
evidence of CNS demyelinating disease beyond meningeal
inflammation (data not shown). Prior to adoptive transfer,
when AQP4-reactive T cells were polarized to a stronger
pro-inflammatory Th17 helper cell phenotype, the clinical
effect was dramatic with leg weakness and paralysis in
addition to a drooping tail with behavioral scores of at
least 2.0 (Fig. 2) and associated weight loss.
Three important controls showed no clinical or histo-
logical phenotype, confirming the specificity of this
model. Adoptive transfer of Th17 polarized AQP4-
reactive T cells from a. unstimulated cultures or b. cul-
tures stimulated with non-specific proteins wasFig. 2 A. Behavioral assessment of adoptive intravenous transfer of T cells
Behavior Score is a 5 point EAE-scale scoring the extent of neurologic disability
with cultured AQP4-restimulated, Th17 polarized AQP4-reactive T cells develop
AQP4-reactive T cells that are not re-stimulated with AQP4 peptide (squar
no behavioral phenotype. B. Daily weights show typical weight loss in mi
T cells (triangles), but not in mice that receive unstimulated (circles) or noharmless highlighting the requirement of AQP4-
peptide during the polarization process (Fig. 2). Patho-
genic AQP4-reactive T cells polarized to Th17 that
were transferred back to naïve AQP4 null mice is also
harmless demonstrating that astrocytic expression of
AQP4 in the host mouse is necessary for this model
(data not shown).
Histologically, in clinically asymptomatic wildtype re-
cipients of unpolarized AQP4-reactive T cells, there were
rare CD3+ T cells scattered in the parenchyma of the
spinal cord, optic nerve and brain (Fig. 3a, d, g), as well
as other AQP4-expressing solid organs such as the lung
(Fig. 3j). In clinically-affected wildtype recipients of
adoptively transferred Th17-polarized AQP4-reactive Tfrom AQP4 null mice immunized against loop C peptide of AQP4. The
(0 is no disability, 5 is death). Wildtype mice (triangles) adoptively transferred
weakness in the tail and hind limbs (EAE score of 1.0–2.0, n = 4). Transfer of
es, n = 5) or stimulated with non-specific proteins (circles, n = 6) show
ce receiving the Th17 polarized AQP4-reactive and AQP4-restimulated
n-AQP4-specifically re-stimulated T cells (squares)
Fig. 3 Histology of tissues from wildtype mice receiving unpolarized AQP4-reactive T cells (A, D, G, J) versus wildtype mice receiving Th17-polarized
AQP4-reactive T cells (B, C, E, F, H, I, K, L). A. Spinal cord parenchyma stained for CD3+ T cells shows rare, scattered cell (arrow), compared to B. spinal
cord sections from wildtype recipients of Th17-polarized AQP4-reactive T cells which shows intense perivascular CD3+ T cell infiltrates. C. Areas of
demyelination (red) within white matter tracts (blue) are visible within inflammatory lesions. D. Longitudinal sections of optic nerves stained for CD3+ T
cells shows rare, scattered cell (arrow), compared to E. optic nerve sections from wildtype recipients of Th17-polarized AQP4-reactive T cells which
shows intense perivascular CD3+ T cell infiltrates (arrow) F. Areas of demyelination (arrow pointing to red) within white matter tracts (blue) are visible
within inflammatory lesions. G. Brain parenchyma stained for CD3+ T cells shows rare, scattered cell (arrow), compared to H. a brain section
from wildtype recipients of Th17-polarized AQP4-reactive T cells which shows intense CD3+ T cell infiltrates, such as this lesion around the 3rd
ventricle (arrow). I. AQP4-reactive T cells do not appear to change AQP4 staining either in lesions or in normal appearing spinal cord, optic
nerve or brain despite widespread inflammation and demyelination (representative section from spinal cord shown). J. Despite expression of
AQP4 in solid organs, rare AQP4-reactive CD3+ T cells appear scattered throughout these organs both in the unpolarized and Th17-polarized
wildtype recipients. Lung from unpolarized shown here with arrow pointing to CD3+ cells. K. Lung section from Th17-polarized recipient showing normal
lung with occasional CD3+ cells (arrow). L. Muscle from Th17 polarized mice show no evidence of inflammation (arrow pointing to rare CD3+ T cells)
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inflammatory infiltrate comprised primarily of CD3+
lymphocytes in the spinal cord, optic nerve and brain.
Inflammation and demyelination in the spinal cord
(Fig. 3b, c) and optic nerves (Fig. 3e, f ) accounted for
the majority of symptoms, but parts of the brainstem,
cerebellum and cerebral cortex showed areas of inflam-
mation that were not as clinically obvious in the mice
(Fig. 3h). Although the AQP4 water channel is targeted
by these pathogenic T cells, astrocytic AQP4 expressionappears relatively intact even within acute inflammatory
lesions (Fig. 3i). Despite AQP4 expression in many other
solid organs, there is no evidence of inflammation or
AQP4 loss outside of the CNS including the lung
(Fig. 3k) or muscles (Fig. 3L) in clinically affected mice.
Blinded quantification of CD3 cells in the spinal cord,
optic nerve, and brain of wildtype recipients of Th17-
polarized AQP4-reactive T cells shows >5-fold more
immunoreactivity (**p<0.01) compared to mice that re-
ceived unpolarized AQP4-reactive T cells (Fig. 4).
Fig. 4 Blinded quantification of CD3 cells in the spinal cord (n = 8), optic
nerve (n = 6) and brain (n = 8) of wildtype recipients of Th17-polarized
AQP4-reactive T cells shows >5-fold more immunoreactivity (**p<0.01)
in these tissues compared to unpolarized mice
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This study demonstrates that adoptive intravenous transfer
of pathogenic AQP4-reactive T cells is sufficient to cause an
NMO-like inflammatory disease that attacks the optic
nerves, spinal cord and brain while sparing other AQP4-
expressing non-CNS organs. Polarization of AQP4-reactive
T cells to a stronger pro-inflammatory Th17 phenotype
prior to transfer amplifies the inflammation leading to more
severe demyelination and neurological dysfunction. The
best explanation for this response is that immunization
with AQP4-loop C peptide in AQP4 null mice generates a
T cell response that is different from immunization of the
same loop in wildtype mice [16]. The AQP4-reactive T
cells in null mice are not exposed to any degree of nega-
tive selection as they likely would be if raised in wildtype
mice. There may also be a protective regulatory response
in wildtype mice that suppresses any potential auto-
reactive tendency.
The implications of this study point to a key immuno-
pathogenic role of Th17 polarized AQP4-reactive T cells
of NMO in both triggering and localizing inflammation
to AQP4 within the central nervous system. Pathogenic
T cells targeting AQP4 do not kill AQP4-expressing
astrocytes and do not cause loss of AQP4 expression.
Rather, their role as demonstrated in this model is to
trigger attacks directed towards AQP4-rich areas of the
CNS and then recruit other components of the immune
system, including antibodies and complement, to medi-
ate the astrocytic damage. In human NMO pathology,
death of astrocytes and loss of aquaporin-4 is a more
downstream event initiated with binding of anti-AQP4
antibody, which leads to either complement-mediateddestruction of the M23 isoform or internalization of the
M1 isoform of AQP4 [17, 18]. We and others have pre-
viously demonstrated a pathogenic function of the anti-
AQP4 antibody in exacerbating neuroinflammation in
rodents, but not in instigating the disease [5–7]. The
specificity of the immune target to the nervous system is
not mediated by the anti-AQP4 antibody as it will bind
AQP4 in any organ [19].
Interestingly, the extracellular loop C is the most com-
mon target of the anti-AQP4 antibody in humans [15].
AQP4-reactive T cells and a pathogenic anti-AQP4 anti-
body may work together to cause NMO. In this model, a
susceptible person is exposed to a peptide corresponding
to loop C of AQP4 under conditions that stimulate both
an auto-reactive T cell and antibody reaction. A pro-
inflammatory Th17 response to AQP4 may cause a more
fulminant disease as demonstrated in this study and pre-
vious animal models [20]. Only after AQP4-reactive T
cells trigger inflammation directed to the optic nerves
and spinal cord would anti-AQP4 antibodies exacerbate
the pathology by fueling complement activation and
granulocyte recruitment.
This model highlights the potential for AQP4-specific
immunotherapy for NMO. As a disease with a highly spe-
cific antigen (AQP4) and antibody response (anti-AQP4)
associated with AQP4-reactive T cells, NMO is poised for
treatment with an antigen-specific therapy [21, 22]. To
induce a tolerance response, high dose soluble loop C pep-
tide may be provided to patients in the setting of immuno-
suppression commonly used to treat NMO currently.
With pre-existing disease, an oral route to achieve muco-
sal tolerance may be the safest initial approach to avoid
worsening the disease [23]. In other diseases with less
antigen-specificity, such as rheumatoid arthritis and mul-
tiple sclerosis, there is significant heterogeneity in the
immunodominant antigen responses; in contrast, NMO is
defined by reaction primarily to the AQP4 water channel
although the precise target within AQP4 may vary slightly
among NMO patients with some patients producing anti-
body responses against loops A and E as well [19]. A study
in Lewis rats in which T cells reactive against loop E could
induce inflammation in the spinal cord suggests that
extracellular targets of AQP4 other than loop C may be
involved [24].
Conclusions
This model demonstrates the potential of AQP4-reactive
T cells to contribute to behavioral disease and to oligoden-
drocyte damage in the central nervous system, independent
of their peripheral role in generating high affinity astrocy-
toxic antibodies. New therapeutic options targeting such
Th17 AQP4-reactive T cell in patients suffering from NMO
could be examined in this model. Further study is required
to determine how oligodendrocytes are killed by T cells
Jones et al. Acta Neuropathologica Communications  (2015) 3:28 Page 8 of 8reactive to an astrocyte protein. Indeed, how Th1 and Th17
T cells indirectly contribute to cellular damage through dir-
ect interactions with the antigen-presenting cells remains an
unanswered question in NMO and multiple sclerosis patho-
genesis. While antibody activation of complement and Fc-
receptor-mediated cytotoxicity are well-established as im-
portant mediators in NMO pathology, this model provides a
tool for examining T cell-mediated antibody-independent
pathways in disease pathogenesis.
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